COMMUNIQUÉS West-GlobeNewswire

First Quarter 2024: Strong growth in US sales of The NGAL Test
08/05/2024
May 8, 2024 Announcement no. 11 First Quarter 2024: Strong growth in US sales of The NGAL Test COPENHAGEN, Denmark and BOSTON, MA, USA, May 8, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S CVR-no. 17500317 (BioPorto or Company [...]
Finnish Hospital Orders Nexstim NBS System 5
08/05/2024
Press release, Helsinki, 8 May 2024 at 9 AM (EEST) Finnish Hospital Orders Nexstim NBS System 5 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a hospital in Finland. This [...]
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations
08/05/2024
COPENHAGEN, Denmark, May 8, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a new share buy-back program, under which the Company intends to buy back up to 162,288 of its own shares. The purpose [...]
Bavarian Nordic Announces Interim Results for the First Three Months of 2024
08/05/2024
COPENHAGEN, Denmark , May 8, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2024. Revenue for the first three months was DKK 831 [...]
Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024
08/05/2024
Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024 Halle (Saale) / Munich, Germany, May 08, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a [...]
Addex to Present at Bio€quity Europe 2024
08/05/2024
Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will [...]
Pharming Group reports first quarter 2024 financial results and provides business update
08/05/2024
First quarter 2024 revenues increased by 31% to US$55.6 million, compared to the first quarter 2023, driven by the U.S. commercial launch of Joenja® and revenue growth of RUCONEST® RUCONEST® revenues increased by 8% to [...]
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
08/05/2024
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its [...]
argenx announces results of Annual General Meeting of Shareholders
07/05/2024
May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced [...]
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/05/2024
BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 1, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting [...]
Jasper Therapeutics to Present at Upcoming Investor Conferences in May
07/05/2024
REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) [...]
DBV Technologies Reports First Quarter 2024 Financial Results and Business Update
07/05/2024
Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024 Appointment of Robert Pietrusko, PharmD to [...]
DBV Technologies publie ses résultats financiers du premier trimestre 2024 et fait le point sur ses activités
07/05/2024
Montrouge, France, le 7 mai DBV Technologies publie ses résultats financiers du premier trimestre 2024 et fait le point sur ses activités Recrutement de VITESSE en bonne voie pour l’inclusion du dernier patient au [...]
Lifeward to Report First Quarter Financial Results on May 15, 2024
07/05/2024
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing [...]
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
07/05/2024
NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and [...]
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
07/05/2024
Met all endpoints in Phase 3 pivotal study for Anaphylm™ (epinephrine) Sublingual Film in first quarter 2024 when compared to EpiPen ® and other injectors used for the treatment of anaphylaxis On track to complete [...]
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
07/05/2024
- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-in-human study expected to start in first half of 2024 - - Clinical trial [...]
Certara Reports First Quarter 2024 Financial Results
07/05/2024
Reiterates Full Year 2024 Financial Guidance PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter [...]
Globus Medical Reports First Quarter 2024 Results
07/05/2024
AUDUBON, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2024. Worldwide net [...]

Pages